Portola Pharmaceuticals (NASDAQ:PTLA) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Thursday.
PTLA has been the topic of several other reports. Oppenheimer reaffirmed a “buy” rating and issued a $80.00 price target on shares of Portola Pharmaceuticals in a research note on Wednesday, September 6th. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $81.00 price target (up from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Finally, Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price target on the stock in a research note on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $71.15.
Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded up $1.66 during mid-day trading on Thursday, reaching $52.71. The company had a trading volume of 580,544 shares, compared to its average volume of 968,181. Portola Pharmaceuticals has a 12 month low of $17.48 and a 12 month high of $67.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTLA. Renaissance Technologies LLC purchased a new stake in shares of Portola Pharmaceuticals in the second quarter worth $21,187,000. Kornitzer Capital Management Inc. KS grew its stake in shares of Portola Pharmaceuticals by 38.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after acquiring an additional 202,925 shares during the last quarter. Zevenbergen Capital Investments LLC grew its stake in shares of Portola Pharmaceuticals by 71.4% in the second quarter. Zevenbergen Capital Investments LLC now owns 452,190 shares of the biopharmaceutical company’s stock worth $25,400,000 after acquiring an additional 188,320 shares during the last quarter. Blue Jay Capital Management LLC purchased a new stake in shares of Portola Pharmaceuticals in the second quarter worth $6,740,000. Finally, State Street Corp lifted its holdings in shares of Portola Pharmaceuticals by 5.3% during the second quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock valued at $117,164,000 after purchasing an additional 105,207 shares in the last quarter. 87.45% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/07/portola-pharmaceuticals-ptla-rating-lowered-to-strong-sell-at-bidaskclub.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.